Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Equity (2016 - 2025)

Historic Return on Equity for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to 0.48%.

  • Altimmune's Return on Equity rose 2400.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 2400.0%. This contributed to the annual value of 0.6% for FY2024, which is 1300.0% down from last year.
  • Latest data reveals that Altimmune reported Return on Equity of 0.48% as of Q3 2025, which was up 2400.0% from 0.58% recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Return on Equity peaked at 0.25% during Q1 2021, and registered a low of 0.74% during Q4 2024.
  • Over the past 5 years, Altimmune's median Return on Equity value was 0.49% (recorded in 2023), while the average stood at 0.51%.
  • Per our database at Business Quant, Altimmune's Return on Equity surged by 3100bps in 2021 and then plummeted by -2800bps in 2022.
  • Over the past 5 years, Altimmune's Return on Equity (Quarter) stood at 0.48% in 2021, then rose by 9bps to 0.43% in 2022, then dropped by -18bps to 0.51% in 2023, then plummeted by -44bps to 0.74% in 2024, then skyrocketed by 35bps to 0.48% in 2025.
  • Its Return on Equity stands at 0.48% for Q3 2025, versus 0.58% for Q2 2025 and 0.68% for Q1 2025.